The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lifecore Biomedical Inc's Score
Industry at a Glance
Industry Ranking
82 / 159
Overall Ranking
231 / 4615
Industry
Pharmaceuticals
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
8.750
Target Price
+29.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Lifecore Biomedical Inc Highlights
StrengthsRisks
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.79% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -5.20, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.26M shares, decreasing 2.40% quarter-over-quarter.
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.